Antineoplastic Agents and (In)fertility: Informing Patients to Improve Decisions

Silva, Cristina; Almeida‐Santos, Teresa; Melo, Claudia de O.; Rama, Ana Cristina Ribeiro

doi:10.1089/jayao.2017.0094

Cited by 3 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies were published between 2009 and 2018 and originated from six countries. One study utilised mixed‐methods design (questionnaires and interviews) while all others were quantitative, utilising online or paper‐based questionnaires . Study type was categorised according to an efficacy and effectiveness rating tool .…”

Section: Resultsmentioning

confidence: 99%

“…Study type was categorised according to an efficacy and effectiveness rating tool . One study was developmental, five contained both stages of development and efficacy, five were efficacy or effectiveness studies, and one was an implementation study …”

Section: Resultsmentioning

confidence: 99%

“…Ten studies recruited cancer patients, one study recruited survivors, and one recruited parents of cancer patients . A variety of health care professionals involved in the care of cancer patients (including oncologists, gynaecologists, and nurses) were recruited by four studies largely to evaluate acceptability and usability of the PtDAs . One study recruited healthy women within the community, and specifically healthy women with lower education, who were asked to make a hypothetical decision about fertility preservation if they were diagnosed with cancer.…”

Section: Resultsmentioning

confidence: 99%

“…Two studies did not specify length of treatment, rather recruited patients based on time since diagnosis (within 5 y), time since fertility preservation decision (at least 1 y ago), or did not specify any patient criteria . Another, detailing a development study, recruited a combination of patients and survivors who were analysed together as the same group and did not specify a time frame since diagnosis …”

Section: Resultsmentioning

confidence: 99%

“…The majority of studies assessed reported sound quality (n = 4 scored 100%; n = 3 scored 75%; n = 2 scored 50%) . One study's quality score was poor (25%); however, this was likely due to the review nature of the study being inadequately appraised by the MMAT, and as such, it was retained for final analysis. Two studies were considered “ grey literature ” in the form of conference abstracts and could not be assessed on quality …”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Systematic review of fertility preservation patient decision aids for cancer patients

2018

View full text Add to dashboard Cite

Objective Despite recommendations internationally for the timely provision of fertility information, cancer patients report unmet information needs, with poor provision and inadequate written information to assist in fertility preservation decision‐making. Patient decision aids (PtDAs) may be a useful resource in this setting to inform patients and guide decision‐making. A systematic review of the literature on decision aids for fertility preservation in cancer patients would determine the effectiveness of these tools in supporting decision‐making about fertility preservation and indicate their current use in clinical care. Methods A systematic review was conducted in March 2018, within electronic search databases Medline, EMBASE, PSYCH Info, PubMed, and Web of Science. An initial search identified 718 potentially relevant articles from databases and screening of relevant reference lists. Results A total of 12 papers, detailing 11 studies with a total of 772 participants, evaluating nine decision aids, were included within the review. PtDAs were shown to significantly increase fertility preservation knowledge and decrease decisional conflict. Overall satisfaction with decision aids was high. Currently, only two reviewed decision aids are available for cancer patients. Another tool has been integrated into a web page, and one implementation study has been completed. Conclusions PtDAs can serve as effective complements to current fertility counselling practices by increasing information satisfaction and decision‐making outcomes. More research is needed into the appropriateness of these resources for patients across the reproductive age range. Future implementation studies may assist in aiding dissemination of these tools into clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review of fertility preservation patient decision aids for cancer patients

2018

View full text Add to dashboard Cite

show abstract

Development and testing of a tailored online fertility preservation decision aid for female cancer patients

et al. 2021

View full text Add to dashboard Cite

show abstract

ESHRE guideline: female fertility preservation†

Anderson

Amant

Braat

et al. 2020

Human Reproduction Open

392

345

View full text Add to dashboard Cite

STUDY QUESTION What is the recommended management for women and transgender men with regards to fertility preservation (FP), based on the best available evidence in the literature? SUMMARY ANSWER The ESHRE Guideline on Female Fertility Preservation makes 78 recommendations on organization of care, information provision and support, pre-FP assessment, FP interventions and after treatment care. Ongoing developments in FP are also discussed. WHAT IS KNOWN ALREADY The field of FP has grown hugely in the last two decades, driven by the increasing recognition of the importance of potential loss of fertility as a significant effect of the treatment of cancer and other serious diseases, and the development of the enabling technologies of oocyte vitrification and ovarian tissue cryopreservation (OTC) for subsequent autografting. This has led to the widespread, though uneven, provision of FP for young women. STUDY DESIGN, SIZE, DURATION The guideline was developed according to the structured methodology for development of ESHRE guidelines. After formulation of key questions by a group of experts, literature searches and assessments were performed. Papers published up to 1 November 2019 and written in English were included in the review. PARTICIPANTS/MATERIALS, SETTING, METHODS Based on the collected evidence, recommendations were formulated and discussed until consensus was reached within the guideline group. A stakeholder review was organized after finalization of the draft. The final version was approved by the guideline group and the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE This guideline aims to help providers meet a growing demand for FP options by diverse groups of patients, including those diagnosed with cancer undergoing gonadotoxic treatments, with benign diseases undergoing gonadotoxic treatments or those with a genetic condition predisposing to premature ovarian insufficiency, transgender men (assigned female at birth), and women requesting oocyte cryopreservation for age-related fertility loss. The guideline makes 78 recommendations on information provision and support, pre-FP assessment, FP interventions and after treatment care, including 50 evidence-based recommendations—of which 31 were formulated as strong recommendations and 19 as weak—25 good practice points and 3 research only recommendations. Of the evidence-based recommendations, 1 was supported by high-quality evidence, 3 by moderate-quality evidence, 17 by low-quality evidence and 29 by very low-quality evidence. To support future research in the field of female FP, a list of research recommendations is provided. LIMITATIONS, REASONS FOR CAUTION Most interventions included are not well studied in FP patients. As some interventions, e.g. oocyte and embryo cryopreservation, are well established for treatment of ...

show abstract

Antineoplastic Agents and (In)fertility: Informing Patients to Improve Decisions

Abstract: Through our multidisciplinary information program, reproductive-age cancer patients now have access to relevant information resources that will support timely, shared decision-making concerning fertility preservation.

Cited by 3 publications

References 41 publications

Systematic review of fertility preservation patient decision aids for cancer patients

Systematic review of fertility preservation patient decision aids for cancer patients

Development and testing of a tailored online fertility preservation decision aid for female cancer patients

ESHRE guideline: female fertility preservation†

Contact Info

Product

Resources

About